Browse drugs

…%) normalised within 6 months as compared to 18/28 (64.3%) with fenofibrate. This was not significantly different between the groups (p=0.4…

…the synergistic effects of a clinically approved PGC1α agonist, bezafibrate, in combination with CAR T cell therapy. This dual treatment dr…

…afibranor initiation. 2 (7.4%) patients continued OCA alongside elafibranor. 19 (70.4%) patients had trialled bezafibrate prior to elafibra…

…UDCA), obeticholic acid (OCA), and amongst those switching from bezafibrate (BZF).Results From Dec 2024 to Nov 2025, 54 pts initiated Ela (…

…py, while 27% were prescribed second-line treatments, including Bezafibrate (31 patients), Obeticholic acid (20 patients), and Elafibranor …

…le therapies Fibrate therapy First (FIB-OCA) OCA therapy First (OCA-FIB) (FIB-OCA) and (OCA-FIB) Comparative p Values ALP M0 (n27) M6 (…

…cribed Ursodeoxycholic acid (UDCA), Obeticholic acid (OCA), and Bezafibrate (BZA), has shown biochemical benefit in patients with inadequat…

…43%) and Caucasian (39%) patients than in Asian patients (26%). Obeticholic acid was more widely prescribed than bezafibrate in all groups. Asia…

…tting. Ileal bile acid transporter (IBAT) inhibitors, including maralixibat, are promising therapies for genetic cholestatic conditions. We…